Clinical Trial Update: Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders [Phase 2]

View source ↗

Summary

A Phase 2 basket study evaluating the efficacy, safety and pharmacokinetics of iptacopan (LNP023) in autoimmune benign hematological disorders was terminated, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Agglutinin Disease
• Immune Thrombocytopenia

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD) | Phase 2 | Status: TERMINATED | Results posted: 2025-03-19